AZD9550 / AstraZeneca - LARVOL DELTA

CONTEMPO: A Trial to Learn How Safe AZD9550 is in People With or Without Type 2 Diabetes Who Are Overweight or Obese (clinicaltrials.gov) - P1/2 | N=88 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: May 2025 ➔ Jul 2026 | Trial primary completion date: May 2025 ➔ Jul 2026

Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Type 2 Diabetes Mellitus

ASCEND: A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: AstraZeneca

New P2 trial • Genetic Disorders • Obesity

Safety and Pharmacokinetics of AZD9550, a GLP-1R/GCGR Dual Agonist, in a First-in-Human Study (OBESITY WEEK 2024) - "Background: Cotadutide was a synthetic once-daily GLP-1R/GCGR dual peptide agonist with a relative potency ratio of approximately 5:1... AZD9550 led to dose-dependent reductions in body weight in obese mice. In healthy participants, there were no safety or tolerability concerns with a pharmacokinetic profile supporting once-weekly dosing. AZD9550 is a novel, investigational drug for obesity with an optimized ratio of glucagon and GLP-1R agonism that is being studied further as a treatment to maximize weight loss and end-organ protection."

Clinical • P1 data • PK/PD data • Genetic Disorders • Obesity • Pain

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: AstraZeneca | Recruiting ➔ Completed

Trial completion • Hepatology • Non-alcoholic Steatohepatitis

CONTEMPO: A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese (clinicaltrials.gov) - P1/2 | N=88 | Recruiting | Sponsor: AstraZeneca

New P1/2 trial • Diabetes • Hepatology • Metabolic Disorders • Non-alcoholic Steatohepatitis • Obesity • Type 2 Diabetes Mellitus

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Non-alcoholic Steatohepatitis

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial • Hepatology • Non-alcoholic Steatohepatitis